APO Research, Inc.

APO RESEARCH · REPORT

Huntington Disease Medications

Selected research

Industry Research

Huntington Disease Medications Industry Research Report 2026

Market perspective

The global Huntington Disease Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Huntington Disease Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Huntington Disease Medications is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Huntington Disease Medications is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Huntington Disease Medications include Teva, Sandoz, Mylan, Zydus, Sun Pharmaceutical, Neurocrine Biosciences, Lupin, Hetero and Dr. Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Huntington Disease Medications market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Huntington Disease Medications Market by Company

Teva

Sandoz

Mylan

Zydus

Sun Pharmaceutical

Neurocrine Biosciences

Lupin

Hetero

Dr. Reddy's Laboratories

Chartwell Pharmaceuticals

Bionpharma

Bausch Health

Apotex

Actavis Laboratories

Huntington Disease Medications Segment by Type

Deutetrabenazine

Tetrabenazine

Valbenazine

Others

Huntington Disease Medications Segment by Application

Hospital and Clinic

Pharmacy

Other

Huntington Disease Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Huntington Disease Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Huntington Disease Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Huntington Disease Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Huntington Disease Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Huntington Disease Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Huntington Disease Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Huntington Disease Medications Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Huntington Disease Medications Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Huntington Disease Medications Sales Market Share by Manufacturers (2021-2026) Table 8. Global Huntington Disease Medications Revenue of Manufacturers (2021-2026) Table 9. Global Huntington Disease Medications Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Huntington Disease Medications Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Huntington Disease Medications Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Huntington Disease Medications, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Huntington Disease Medications, Product Type & Application Table 14. Global Huntington Disease Medications Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Huntington Disease Medications by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Company Information Table 19. Teva Business Overview Table 20. Teva Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Teva Huntington Disease Medications Product Portfolio Table 22. Teva Recent Developments Table 23. Sandoz Company Information Table 24. Sandoz Business Overview Table 25. Sandoz Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Sandoz Huntington Disease Medications Product Portfolio Table 27. Sandoz Recent Developments Table 28. Mylan Company Information Table 29. Mylan Business Overview Table 30. Mylan Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Mylan Huntington Disease Medications Product Portfolio Table 32. Mylan Recent Developments Table 33. Zydus Company Information Table 34. Zydus Business Overview Table 35. Zydus Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Zydus Huntington Disease Medications Product Portfolio Table 37. Zydus Recent Developments Table 38. Sun Pharmaceutical Company Information Table 39. Sun Pharmaceutical Business Overview Table 40. Sun Pharmaceutical Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Sun Pharmaceutical Huntington Disease Medications Product Portfolio Table 42. Sun Pharmaceutical Recent Developments Table 43. Neurocrine Biosciences Company Information Table 44. Neurocrine Biosciences Business Overview Table 45. Neurocrine Biosciences Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Neurocrine Biosciences Huntington Disease Medications Product Portfolio Table 47. Neurocrine Biosciences Recent Developments Table 48. Lupin Company Information Table 49. Lupin Business Overview Table 50. Lupin Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lupin Huntington Disease Medications Product Portfolio Table 52. Lupin Recent Developments Table 53. Hetero Company Information Table 54. Hetero Business Overview Table 55. Hetero Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Hetero Huntington Disease Medications Product Portfolio Table 57. Hetero Recent Developments Table 58. Dr. Reddy's Laboratories Company Information Table 59. Dr. Reddy's Laboratories Business Overview Table 60. Dr. Reddy's Laboratories Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Dr. Reddy's Laboratories Huntington Disease Medications Product Portfolio Table 62. Dr. Reddy's Laboratories Recent Developments Table 63. Chartwell Pharmaceuticals Company Information Table 64. Chartwell Pharmaceuticals Business Overview Table 65. Chartwell Pharmaceuticals Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Chartwell Pharmaceuticals Huntington Disease Medications Product Portfolio Table 67. Chartwell Pharmaceuticals Recent Developments Table 68. Bionpharma Company Information Table 69. Bionpharma Business Overview Table 70. Bionpharma Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bionpharma Huntington Disease Medications Product Portfolio Table 72. Bionpharma Recent Developments Table 73. Bausch Health Company Information Table 74. Bausch Health Business Overview Table 75. Bausch Health Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Bausch Health Huntington Disease Medications Product Portfolio Table 77. Bausch Health Recent Developments Table 78. Apotex Company Information Table 79. Apotex Business Overview Table 80. Apotex Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Apotex Huntington Disease Medications Product Portfolio Table 82. Apotex Recent Developments Table 83. Actavis Laboratories Company Information Table 84. Actavis Laboratories Business Overview Table 85. Actavis Laboratories Huntington Disease Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Actavis Laboratories Huntington Disease Medications Product Portfolio Table 87. Actavis Laboratories Recent Developments Table 88. Global Huntington Disease Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Huntington Disease Medications Sales by Region (2021-2026) & (K Units) Table 90. Global Huntington Disease Medications Sales Market Share by Region (2021-2026) Table 91. Global Huntington Disease Medications Sales by Region (2027-2032) & (K Units) Table 92. Global Huntington Disease Medications Sales Market Share by Region (2027-2032) Table 93. Global Huntington Disease Medications Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Huntington Disease Medications Revenue Market Share by Region (2021-2026) Table 95. Global Huntington Disease Medications Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Huntington Disease Medications Revenue Market Share by Region (2027-2032) Table 97. North America Huntington Disease Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 99. North America Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 100. North America Huntington Disease Medications Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Huntington Disease Medications Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Huntington Disease Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 104. Europe Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 105. Europe Huntington Disease Medications Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Huntington Disease Medications Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Huntington Disease Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Huntington Disease Medications Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Huntington Disease Medications Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Huntington Disease Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 114. South America Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 115. South America Huntington Disease Medications Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Huntington Disease Medications Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Huntington Disease Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Huntington Disease Medications Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Huntington Disease Medications Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Huntington Disease Medications Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Huntington Disease Medications Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Huntington Disease Medications Sales by Type (2021-2026) & (K Units) Table 123. Global Huntington Disease Medications Sales by Type (2027-2032) & (K Units) Table 124. Global Huntington Disease Medications Sales Market Share by Type (2021-2026) Table 125. Global Huntington Disease Medications Sales Market Share by Type (2027-2032) Table 126. Global Huntington Disease Medications Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Huntington Disease Medications Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Huntington Disease Medications Revenue Market Share by Type (2021-2026) Table 129. Global Huntington Disease Medications Revenue Market Share by Type (2027-2032) Table 130. Global Huntington Disease Medications Price by Type (2021-2026) & (US$/Unit) Table 131. Global Huntington Disease Medications Price by Type (2027-2032) & (US$/Unit) Table 132. Global Huntington Disease Medications Sales by Application (2021-2026) & (K Units) Table 133. Global Huntington Disease Medications Sales by Application (2027-2032) & (K Units) Table 134. Global Huntington Disease Medications Sales Market Share by Application (2021-2026) Table 135. Global Huntington Disease Medications Sales Market Share by Application (2027-2032) Table 136. Global Huntington Disease Medications Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Huntington Disease Medications Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Huntington Disease Medications Revenue Market Share by Application (2021-2026) Table 139. Global Huntington Disease Medications Revenue Market Share by Application (2027-2032) Table 140. Global Huntington Disease Medications Price by Application (2021-2026) & (US$/Unit) Table 141. Global Huntington Disease Medications Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Huntington Disease Medications Distributors List Table 145. Huntington Disease Medications Customers List Table 146. Huntington Disease Medications Industry Trends Table 147. Huntington Disease Medications Industry Drivers Table 148. Huntington Disease Medications Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Huntington Disease Medications Product Image Figure 5. Global Huntington Disease Medications Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Huntington Disease Medications Market Size (2021-2032) & (US$ Million) Figure 7. Global Huntington Disease Medications Sales (2021-2032) & (K Units) Figure 8. Global Huntington Disease Medications Average Price (US$/Unit) & (2021-2032) Figure 9. Deutetrabenazine Product Image Figure 10. Tetrabenazine Product Image Figure 11. Valbenazine Product Image Figure 12. Others Product Image Figure 13. Hospital and Clinic Product Image Figure 14. Pharmacy Product Image Figure 15. Other Product Image Figure 16. Global Huntington Disease Medications Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Huntington Disease Medications, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Huntington Disease Medications Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Huntington Disease Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Huntington Disease Medications Sales by Region in 2025 Figure 22. Global Huntington Disease Medications Revenue by Region in 2025 Figure 23. North America Huntington Disease Medications Market Size by Country in 2025 Figure 24. North America Huntington Disease Medications Sales Market Share by Country (2021-2032) Figure 25. North America Huntington Disease Medications Revenue Market Share by Country (2021-2032) Figure 26. United States Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Huntington Disease Medications Market Size by Country in 2025 Figure 30. Europe Huntington Disease Medications Sales Market Share by Country (2021-2032) Figure 31. Europe Huntington Disease Medications Revenue Market Share by Country (2021-2032) Figure 32. Germany Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Huntington Disease Medications Market Size by Country in 2025 Figure 43. Asia Pacific Huntington Disease Medications Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Huntington Disease Medications Revenue Market Share by Country (2021-2032) Figure 45. China Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Huntington Disease Medications Market Size by Country in 2025 Figure 54. South America Huntington Disease Medications Sales Market Share by Country (2021-2032) Figure 55. South America Huntington Disease Medications Revenue Market Share by Country (2021-2032) Figure 56. Brazil Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Huntington Disease Medications Market Size by Country in 2025 Figure 60. Middle East and Africa Huntington Disease Medications Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Huntington Disease Medications Revenue Market Share by Country (2021-2032) Figure 62. Egypt Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Huntington Disease Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Huntington Disease Medications Sales Market Share by Type (2021-2032) Figure 68. Global Huntington Disease Medications Revenue Market Share by Type (2021-2032) Figure 69. Global Huntington Disease Medications Price (US$/Unit) by Type (2021-2032) Figure 70. Global Huntington Disease Medications Sales Market Share by Application (2021-2032) Figure 71. Global Huntington Disease Medications Revenue Market Share by Application (2021-2032) Figure 72. Global Huntington Disease Medications Price (US$/Unit) by Application (2021-2032) Figure 73. Huntington Disease Medications Value Chain Figure 74. Huntington Disease Medications Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Huntington Disease Medications Industry Opportunities and Challenges

Scope & coverage.

Types
  • Deutetrabenazine
  • Tetrabenazine
  • Valbenazine
  • Others
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Teva
  • Sandoz
  • Mylan
  • Zydus
  • Sun Pharmaceutical
  • Neurocrine Biosciences
  • Lupin
  • Hetero
  • Dr. Reddy's Laboratories
  • Chartwell Pharmaceuticals
  • Bionpharma
  • Bausch Health
  • Apotex
  • Actavis Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Huntington Disease Medications Market Size (2021-2032)
  4. 2.2.2 Global Huntington Disease Medications Sales (2021-2032)
  5. 2.2.3 Global Huntington Disease Medications Market Average Price (2021-2032)
  6. 2.3 Huntington Disease Medications by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Deutetrabenazine
  9. 2.3.3 Tetrabenazine
  10. 2.3.4 Valbenazine
  11. 2.3.5 Others
  12. 2.4 Huntington Disease Medications by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital and Clinic
  15. 2.4.3 Pharmacy
  16. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Huntington Disease Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Huntington Disease Medications Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Huntington Disease Medications Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Huntington Disease Medications Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Huntington Disease Medications Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Huntington Disease Medications, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Huntington Disease Medications, Product Type & Application
  8. 3.8 Global Manufacturers of Huntington Disease Medications, Established Date
  9. 3.9 Global Huntington Disease Medications Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva
  2. 4.1.1 Teva Company Information
  3. 4.1.2 Teva Business Overview
  4. 4.1.3 Teva Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Huntington Disease Medications Product Portfolio
  6. 4.1.5 Teva Recent Developments
  7. 4.2 Sandoz
  8. 4.2.1 Sandoz Company Information
  9. 4.2.2 Sandoz Business Overview
  10. 4.2.3 Sandoz Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sandoz Huntington Disease Medications Product Portfolio
  12. 4.2.5 Sandoz Recent Developments
  13. 4.3 Mylan
  14. 4.3.1 Mylan Company Information
  15. 4.3.2 Mylan Business Overview
  16. 4.3.3 Mylan Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Mylan Huntington Disease Medications Product Portfolio
  18. 4.3.5 Mylan Recent Developments
  19. 4.4 Zydus
  20. 4.4.1 Zydus Company Information
  21. 4.4.2 Zydus Business Overview
  22. 4.4.3 Zydus Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Zydus Huntington Disease Medications Product Portfolio
  24. 4.4.5 Zydus Recent Developments
  25. 4.5 Sun Pharmaceutical
  26. 4.5.1 Sun Pharmaceutical Company Information
  27. 4.5.2 Sun Pharmaceutical Business Overview
  28. 4.5.3 Sun Pharmaceutical Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sun Pharmaceutical Huntington Disease Medications Product Portfolio
  30. 4.5.5 Sun Pharmaceutical Recent Developments
  31. 4.6 Neurocrine Biosciences
  32. 4.6.1 Neurocrine Biosciences Company Information
  33. 4.6.2 Neurocrine Biosciences Business Overview
  34. 4.6.3 Neurocrine Biosciences Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Neurocrine Biosciences Huntington Disease Medications Product Portfolio
  36. 4.6.5 Neurocrine Biosciences Recent Developments
  37. 4.7 Lupin
  38. 4.7.1 Lupin Company Information
  39. 4.7.2 Lupin Business Overview
  40. 4.7.3 Lupin Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lupin Huntington Disease Medications Product Portfolio
  42. 4.7.5 Lupin Recent Developments
  43. 4.8 Hetero
  44. 4.8.1 Hetero Company Information
  45. 4.8.2 Hetero Business Overview
  46. 4.8.3 Hetero Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hetero Huntington Disease Medications Product Portfolio
  48. 4.8.5 Hetero Recent Developments
  49. 4.9 Dr. Reddy's Laboratories
  50. 4.9.1 Dr. Reddy's Laboratories Company Information
  51. 4.9.2 Dr. Reddy's Laboratories Business Overview
  52. 4.9.3 Dr. Reddy's Laboratories Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Dr. Reddy's Laboratories Huntington Disease Medications Product Portfolio
  54. 4.9.5 Dr. Reddy's Laboratories Recent Developments
  55. 4.10 Chartwell Pharmaceuticals
  56. 4.10.1 Chartwell Pharmaceuticals Company Information
  57. 4.10.2 Chartwell Pharmaceuticals Business Overview
  58. 4.10.3 Chartwell Pharmaceuticals Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Chartwell Pharmaceuticals Huntington Disease Medications Product Portfolio
  60. 4.10.5 Chartwell Pharmaceuticals Recent Developments
  61. 4.11 Bionpharma
  62. 4.11.1 Bionpharma Company Information
  63. 4.11.2 Bionpharma Business Overview
  64. 4.11.3 Bionpharma Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Bionpharma Huntington Disease Medications Product Portfolio
  66. 4.11.5 Bionpharma Recent Developments
  67. 4.12 Bausch Health
  68. 4.12.1 Bausch Health Company Information
  69. 4.12.2 Bausch Health Business Overview
  70. 4.12.3 Bausch Health Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Bausch Health Huntington Disease Medications Product Portfolio
  72. 4.12.5 Bausch Health Recent Developments
  73. 4.13 Apotex
  74. 4.13.1 Apotex Company Information
  75. 4.13.2 Apotex Business Overview
  76. 4.13.3 Apotex Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Apotex Huntington Disease Medications Product Portfolio
  78. 4.13.5 Apotex Recent Developments
  79. 4.14 Actavis Laboratories
  80. 4.14.1 Actavis Laboratories Company Information
  81. 4.14.2 Actavis Laboratories Business Overview
  82. 4.14.3 Actavis Laboratories Huntington Disease Medications Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Actavis Laboratories Huntington Disease Medications Product Portfolio
  84. 4.14.5 Actavis Laboratories Recent Developments
5 Global Huntington Disease Medications Market Scenario by Region
  1. 5.1 Global Huntington Disease Medications Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Huntington Disease Medications Sales by Region: 2021-2032
  3. 5.2.1 Global Huntington Disease Medications Sales by Region: 2021-2026
  4. 5.2.2 Global Huntington Disease Medications Sales by Region: 2027-2032
  5. 5.3 Global Huntington Disease Medications Revenue by Region: 2021-2032
  6. 5.3.1 Global Huntington Disease Medications Revenue by Region: 2021-2026
  7. 5.3.2 Global Huntington Disease Medications Revenue by Region: 2027-2032
  8. 5.4 North America Huntington Disease Medications Market Facts & Figures by Country
  9. 5.4.1 North America Huntington Disease Medications Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Huntington Disease Medications Sales by Country (2021-2032)
  11. 5.4.3 North America Huntington Disease Medications Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Huntington Disease Medications Market Facts & Figures by Country
  16. 5.5.1 Europe Huntington Disease Medications Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Huntington Disease Medications Sales by Country (2021-2032)
  18. 5.5.3 Europe Huntington Disease Medications Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Huntington Disease Medications Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Huntington Disease Medications Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Huntington Disease Medications Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Huntington Disease Medications Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Huntington Disease Medications Market Facts & Figures by Country
  41. 5.7.1 South America Huntington Disease Medications Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Huntington Disease Medications Sales by Country (2021-2032)
  43. 5.7.3 South America Huntington Disease Medications Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Huntington Disease Medications Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Huntington Disease Medications Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Huntington Disease Medications Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Huntington Disease Medications Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Huntington Disease Medications Sales by Type (2021-2032)
  2. 6.1.1 Global Huntington Disease Medications Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Huntington Disease Medications Sales Market Share by Type (2021-2032)
  4. 6.2 Global Huntington Disease Medications Revenue by Type (2021-2032)
  5. 6.2.1 Global Huntington Disease Medications Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Huntington Disease Medications Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Huntington Disease Medications Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Huntington Disease Medications Sales by Application (2021-2032)
  2. 7.1.1 Global Huntington Disease Medications Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Huntington Disease Medications Sales Market Share by Application (2021-2032)
  4. 7.2 Global Huntington Disease Medications Revenue by Application (2021-2032)
  5. 7.2.1 Global Huntington Disease Medications Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Huntington Disease Medications Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Huntington Disease Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Huntington Disease Medications Value Chain Analysis
  2. 8.1.1 Huntington Disease Medications Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Huntington Disease Medications Production Mode & Process
  5. 8.2 Huntington Disease Medications Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Huntington Disease Medications Distributors
  8. 8.2.3 Huntington Disease Medications Customers
9 Global Huntington Disease Medications Analyzing Market Dynamics
  1. 9.1 Huntington Disease Medications Industry Trends
  2. 9.2 Huntington Disease Medications Industry Drivers
  3. 9.3 Huntington Disease Medications Industry Opportunities and Challenges
  4. 9.4 Huntington Disease Medications Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.